Airway Medix S.A. focuses on research and development work and commercialisation of innovative, disposable devices for the mechanically ventilated patients in the Intensive Care Units (ICU), and for the patients in life-threatening conditions in the anaesthesiology departments.
The family of products developed by Airway Medix is aimed at limiting the growth of a biofilm in patients, reducing the microbial flora in the oral cavity and improving the fitting and tightness of intubation tubes. By reducing biofilm formation and preventing entry of infected material into the lungs, the products protect patients from acquiring Ventilation Associated Pneumonia (VAP).
Ventilation Associated Pneumonia is considered one of the most serious and most costly hospital-acquired infections. The low effectiveness of devices currently available on the market supports the large numbers of patients with VAP and unnecessarily extended ventilation even in the best departments of the best hospitals, as well as ineffective and time-consuming work of the nursing staff.
Products presented by Airway Medix address the immediate clinical needs and make up for the shortcomings in the area of currently applied medical devices. They provide the patients, their carers and healthcare financing institutions with considerable clinical and economic benefits.
The Company conducts research and development work in a R&D laboratory certified according to (ISO 13485:2003 & EN ISO 13485:2012) located in Israel, https://www.biovo-tech.com/
